Robins Kaplan LLP is pleased to announce that Jake Holdreith has been named 2023 “Minnesota Litigator of the Year” by Managing IP in its 18th annual awards. Additionally, Robins Kaplan was shortlisted for “Firm of the Year” in the following categories: Life Sciences IP Litigation (U.S. National), Patent Disputes (Midwest), and Trademark Disputes (Midwest).
According to Managing IP, its annual awards are presented to firms, individuals, and companies behind the most innovative and challenging intellectual property work of the past year, as well as those driving the international IP market.
Jake Holdreith leads the firm’s Health and Life Sciences Industry Group and serves as a member of the Executive Board. He is a known strategist and skilled courtroom lawyer who has tried jury cases to multi-million-dollar verdicts and has resolved complex cases at all stages of litigation. In 2022, he led a trial team representing University of Pennsylvania in a patent infringement action against Eli Lilly and ImClone related to the treatment of certain cancers with Erbitux, and represented Bioeq AG with resapect to certain IP matters for licensing Biologics License Application Number 761165 for a biosimilar to CIMERLI™ (ranibizumab-eqrn).
He also served as court-appointed co-lead trial counsel leading a trial team that achieved settlements in excess of $118 million on behalf of U.S. contact lens purchasers in an expansive antitrust class action against the four dominant manufacturers and the largest nationwide distributor of contact lenses.
Holdreith has been recognized for his achievements and leadership skills by multiple publications. In 2022 alone, he was named “Hatch-Waxman Litigator of the Year” by LMG Life Sciences, selected to the “IAM Strategy 300 Global Leaders Guide,” named a “Litigation Star” by Benchmark Litigation, received the “Patent Impact Case of the Year” award from LMG Life Sciences, and named an “Attorney of the Year” by The Best Lawyers in America.
Related Attorneys
Partner
